Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
- Status
- WITHDRAWN
- Phase
- PHASE2
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
- Status
- TERMINATED
- Phase
- PHASE1
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
- Status
- COMPLETED
- Phase
- N/A
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- Status
- TERMINATED
- Phase
- PHASE2
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
- Status
- COMPLETED
- Phase
- PHASE1